Ursodeoxycholyl lysophosphatidylethanolamide attenuates hepatofibrogenesis by impairment of TGF-β1/Smad2/3 signalling

British Journal of Pharmacology

Volumn 171, Issue 22, 2014, Pages 5113-5126

  Pathil, Anita ^a   Mueller, Jan ^a   Ludwig, Johannes M ^a   Wang, Jiliang ^a   Warth, Arne ^a   Chamulitrat, Walee ^a   Stremmel, Wolfgang ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLINE; COLLAGEN TYPE 1; COLLAGEN TYPE 1ALPHA; CYCLOHEXIMIDE; METHIONINE; SMAD2 PROTEIN; SMAD3 PROTEIN; SMOOTH MUSCLE ACTIN; TRANSFORMING GROWTH FACTOR BETA1; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; URSODEOXYCHOLIC ACID DERIVATIVE; URSODEOXYCHOLYLLYSOPHOSPHATIDYLETHANOLAMIDE; ACTA2 PROTEIN, HUMAN; ACTIN; ANTIINFLAMMATORY AGENT; LYSOPHOSPHOLIPID; SMAD2 PROTEIN, HUMAN; SMAD3 PROTEIN, HUMAN; URSODEOXYCHOLIC ACID; URSODEOXYCHOLYL LYSOPHOSPHATIDYLETHANOLAMIDE; VIMENTIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOACCUMULATION; CELL STRESS; CELLULAR STRESS RESPONSE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CULTURE MEDIUM; DOWN REGULATION; DRUG EFFICACY; DRUG MECHANISM; DRUG PROTEIN BINDING; DRUG TARGETING; EXTRACELLULAR MATRIX; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LIVER CELL CULTURE; LIVER FIBROSIS; LIVER PROTECTION; MALE; MOUSE; MOUSE MODEL; NONALCOHOLIC FATTY LIVER; NONHUMAN; PHARMACOLOGICAL BLOCKING; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; STELLATE CELL; TREATMENT DURATION; ANALOGS AND DERIVATIVES; ANIMAL; C57BL MOUSE; CELL LINE; CHEMISTRY; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; LIVER CIRRHOSIS; METABOLISM;

ACTINS; ANIMALS; ANTI-INFLAMMATORY AGENTS; CELL LINE; COLLAGEN TYPE I; GENE EXPRESSION REGULATION; HEPATIC STELLATE CELLS; HUMANS; LIVER CIRRHOSIS; LYSOPHOSPHOLIPIDS; MALE; MICE, INBRED C57BL; SIGNAL TRANSDUCTION; SMAD2 PROTEIN; SMAD3 PROTEIN; TRANSFORMING GROWTH FACTOR BETA1; URSODEOXYCHOLIC ACID; VIMENTIN;

EID: 84915753244     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/bph.12837     Document Type: Article

References (50)

1. Alexander SPH, Benson HE, Faccenda E, Pawson AJ, Sharman JL, Spedding M et al. (2013). The Concise Guide to PHARMACOLOGY 2013/14: Enzymes. Br J Pharmacol 170: 1797-1867.
2. Angulo P (2002). Nonalcoholic fatty liver disease. N Engl J Med 346: 1221-1231.
3. Bataller R, Brenner DA (2005). Liver fibrosis. J Clin Invest 115: 209-218.
4. Blobe GC, Schiemann WP, Lodish HF (2000). Role of transforming growth factor beta in human disease. N Engl J Med 342: 1350-1358.
5. Canbay A, Taimr P, Torok N, Higuchi H, Friedman S, Gores GJ (2003). Apoptotic body engulfment by a human stellate cell line is profibrogenic. Lab Invest 83: 655-663.
6. Chamulitrat W, Burhenne J, Rehlen T, Pathil A, Stremmel W (2009). Bile salt-phospholipid conjugate ursodeoxycholyl lysophosphatidylethanolamide as a hepatoprotective agent. Hepatology 50: 143-154.
7. Chamulitrat W, Liebisch G, Xu W, Gan-Schreier H, Pathil A, Schmitz G et al. (2013). Ursodeoxycholyl lysophosphatidylethanolamide inhibits lipoapoptosis by shifting fatty acid pools toward monosaturated and polyunsaturated fatty acids in mouse hepatocytes. Mol Pharmacol 84: 696-709.
8. Chen YG (2009). Endocytic regulation of TGF-beta signaling. Cell Res 19: 58-70.
9. Clark JM, Diehl AM (2003). Nonalcoholic fatty liver disease: an underrecognized cause of cryptogenic cirrhosis. JAMA 289: 3000-3004.
10. Derynck R, Zhang YE (2003). Smad-dependent and Smad-independent pathways in TGF-beta family signalling. Nature 425: 577-584.
11. Di Guglielmo GM, Le Roy C, Goodfellow AF, Wrana JL (2003). Distinct endocytic pathways regulate TGF-beta receptor signalling and turnover. Nat Cell Biol 5: 410-421.
12. Dooley S, Delvoux B, Streckert M, Bonzel L, Stopa M, ten Dijke P et al. (2001). Transforming growth factor beta signal transduction in hepatic stellate cells via Smad2/3 phosphorylation, a pathway that is abrogated during in vitro progression to myofibroblasts. TGFbeta signal transduction during transdifferentiation of hepatic stellate cells. FEBS Lett 502: 4-10.
13. Dooley S, Hamzavi J, Breitkopf K, Wiercinska E, Said HM, Lorenzen J et al. (2003). Smad7 prevents activation of hepatic stellate cells and liver fibrosis in rats. Gastroenterology 125: 178-191.
14. Fiorucci S, Mencarelli A, Palazzetti B, Del Soldato P, Morelli A, Ignarro LJ (2001). An NO derivative of ursodeoxycholic acid protects against Fas-mediated liver injury by inhibiting caspase activity. Proc Natl Acad Sci U S A 98: 2652-2657.
15. Furukawa F, Matsuzaki K, Mori S, Tahashi Y, Yoshida K, Sugano Y et al. (2003). p38 MAPK mediates fibrogenic signal through Smad3 phosphorylation in rat myofibroblasts. Hepatology 38: 879-889.
16. George J, Pera N, Phung N, Leclercq I, Yun Hou J, Farrell G (2003). Lipid peroxidation, stellate cell activation and hepatic fibrogenesis in a rat model of chronic steatohepatitis. J Hepatol 39: 756-764.
17. Goto M, Okamoto Y, Yamamoto M, Aki H (2001). Anti-inflammatory effects of 5-aminosalicylic acid conjugates with chenodeoxycholic acid and ursodeoxycholic acid on carrageenan-induced colitis in guinea-pigs. J Pharm Pharmacol 53: 1711-1720.
18. Gressner OA, Lahme B, Rehbein K, Siluschek M, Weiskirchen R, Gressner AM (2008). Pharmacological application of caffeine inhibits TGF-beta-stimulated connective tissue growth factor expression in hepatocytes via PPARgamma and SMAD2/3-dependent pathways. J Hepatol 49: 758-767.
19. Inagaki Y, Mamura M, Kanamaru Y, Greenwel P, Nemoto T, Takehara K et al. (2001). Constitutive phosphorylation and nuclear localization of Smad3 are correlated with increased collagen gene transcription in activated hepatic stellate cells. J Cell Physiol 187: 117-123.
20. Kaimori A, Potter J, Kaimori JY, Wang C, Mezey E, Koteish A (2007). Transforming growth factor-beta1 induces an epithelial-to-mesenchymal transition state in mouse hepatocytes in vitro. J Biol Chem 282: 22089-22101.
21. Kalluri R, Neilson EG (2003). Epithelial-mesenchymal transition and its implications for fibrosis. J Clin Invest 112: 1776-1784.
22. Kilkenny C, Browne W, Cuthill IC, Emerson M, Altman DG (2010). Animal research: reporting in vivo experiments: the ARRIVE guidelines. Br J Pharmacol 160: 1577-1579.
23. Kohli R, Pan X, Malladi P, Wainwright MS, Whitington PF (2007). Mitochondrial reactive oxygen species signal hepatocyte steatosis by regulating the phosphatidylinositol 3-kinase cell survival pathway. J Biol Chem 282: 21327-21336.
24. Kretzschmar M, Doody J, Massague J (1997). Opposing BMP and EGF signalling pathways converge on the TGF-beta family mediator Smad1. Nature 389: 618-622.
25. Leask A, Abraham DJ (2006). All in the CCN family: essential matricellular signaling modulators emerge from the bunker. J Cell Sci 119 (Pt 23): 4803-4810.
26. Li F, Zeng B, Chai Y, Cai P, Fan C, Cheng T (2009). The linker region of Smad2 mediates TGF-beta-dependent ERK2-induced collagen synthesis. Biochem Biophys Res Commun 386: 289-293.
27. Li J, Kim CI, Leo MA, Mak KM, Rojkind M, Lieber CS (1992). Polyunsaturated lecithin prevents acetaldehyde-mediated hepatic collagen accumulation by stimulating collagenase activity in cultured lipocytes. Hepatology 15: 373-381.
28. Lieber CS, Robins SJ, Li J, DeCarli LM, Mak KM, Fasulo JM et al. (1994). Phosphatidylcholine protects against fibrosis and cirrhosis in the baboon. Gastroenterology 106: 152-159.
29. Lo RS, Massague J (1999). Ubiquitin-dependent degradation of TGF-beta-activated smad2. Nat Cell Biol 1: 472-478.
30. Ma X, Zhao J, Lieber CS (1996). Polyenylphosphatidylcholine attenuates non-alcoholic hepatic fibrosis and accelerates its regression. J Hepatol 24: 604-613.
31. Malhi H, Gores GJ (2008). Cellular and molecular mechanisms of liver injury. Gastroenterology 134: 1641-1654.
32. McGrath J, Drummond G, McLachlan E, Kilkenny C, Wainwright C (2010). Guidelines for reporting experiments involving animals: the ARRIVE guidelines. Br J Pharmacol 160: 1573-1576.
33. Mori S, Matsuzaki K, Yoshida K, Furukawa F, Tahashi Y, Yamagata H et al. (2004). TGF-beta and HGF transmit the signals through JNK-dependent Smad2/3 phosphorylation at the linker regions. Oncogene 23: 7416-7429.
34. Moustakas A, Souchelnytskyi S, Heldin CH (2001). Smad regulation in TGF-beta signal transduction. J Cell Sci 114 (Pt 24): 4359-4369.
35. Nakao A, Afrakhte M, Moren A, Nakayama T, Christian JL, Heuchel R et al. (1997). Identification of Smad7, a TGFbeta-inducible antagonist of TGF-beta signalling. Nature 389: 631-635.
36. Oneta CM, Mak KM, Lieber CS (1999). Dilinoleoylphosphatidylcholine selectively modulates lipopolysaccharide-induced Kupffer cell activation. J Lab Clin Med 134: 466-470.
37. Pathil A, Mueller J, Warth A, Chamulitrat W, Stremmel W (2012). Ursodeoxycholyl lysophosphatidylethanolamide improves steatosis and inflammation in murine models of nonalcoholic fatty liver disease. Hepatology 55: 1369-1378.
38. Pathil A, Warth A, Chamulitrat W, Stremmel W (2011). The synthetic bile acid-phospholipid conjugate ursodeoxycholyl lysophosphatidylethanolamide suppresses TNFalpha-induced liver injury. J Hepatol 54: 674-684.
39. Pawson AJ, Sharman JL, Benson HE, Faccenda E, Alexander SP, Buneman OP et al.; NC-IUPHAR (2014). The IUPHAR/BPS Guide to PHARMACOLOGY: an expert-driven knowledge base of drug targets and their ligands. Nucl Acids Res 42 (Database Issue): D1098-D1106.
40. Reunanen N, Foschi M, Han J, Kahari VM (2000). Activation of extracellular signal-regulated kinase 1/2 inhibits type I collagen expression by human skin fibroblasts. J Biol Chem 275: 34634-34639.
41. Rinella ME, Elias MS, Smolak RR, Fu T, Borensztajn J, Green RM (2008). Mechanisms of hepatic steatosis in mice fed a lipogenic methionine choline-deficient diet. J Lipid Res 49: 1068-1076.
42. Sapkota G, Knockaert M, Alarcon C, Montalvo E, Brivanlou AH, Massague J (2006). Dephosphorylation of the linker regions of Smad1 and Smad2/3 by small C-terminal domain phosphatases has distinct outcomes for bone morphogenetic protein and transforming growth factor-beta pathways. J Biol Chem 281: 40412-40419.
43. Schnabl B, Kweon YO, Frederick JP, Wang XF, Rippe RA, Brenner DA (2001). The role of Smad3 in mediating mouse hepatic stellate cell activation. Hepatology 34: 89-100.
44. Shi Y, Massague J (2003). Mechanisms of TGF-beta signaling from cell membrane to the nucleus. Cell 113: 685-700.
45. Thiery JP, Sleeman JP (2006). Complex networks orchestrate epithelial-mesenchymal transitions. Nat Rev Mol Cell Biol 7: 131-142.
46. Treede I, Braun A, Sparla R, Kuhnel M, Giese T, Turner JR et al. (2007). Anti-inflammatory effects of phosphatidylcholine. J Biol Chem 282: 27155-27164.
47. Wrana JL, Attisano L, Wieser R, Ventura F, Massague J (1994). Mechanism of activation of the TGF-beta receptor. Nature 370: 341-347.
48. Wrighton KH, Lin X, Feng XH (2009). Phospho-control of TGF-beta superfamily signaling. Cell Res 19: 8-20.
49. Xu L, Hui AY, Albanis E, Arthur MJ, O'Byrne SM, Blaner WS et al. (2005). Human hepatic stellate cell lines, LX-1 and LX-2: new tools for analysis of hepatic fibrosis. Gut 54: 142-151.
50. Zhang Y, Chang C, Gehling DJ, Hemmati-Brivanlou A, Derynck R (2001). Regulation of Smad degradation and activity by Smurf2, an E3 ubiquitin ligase. Proc Natl Acad Sci U S A 98: 974-979.